Patients have a right to decline or withdraw LVADs. Informed consent and shared decision making is not easy, however, with treatments that are high risk, high reward.
AMA J Ethics. 2019;21(5):E394-400. doi:
10.1001/amajethics.2019.394.
The DSM-5 Task Force’s handling of the ethical controversy over the bereavement exclusion demonstrates the need for more inclusive deliberative processes.
AMA J Ethics. 2017;19(2):192-198. doi:
10.1001/journalofethics.2017.19.2.pfor2-1702.
Physicians, committees, and guardians all make decisions for unrepresented patients in the US. This article considers a “tiered” approach as an alternative.
AMA J Ethics. 2019;21(7):E587-593. doi:
10.1001/amajethics.2019.587.
When patients are unable to express their wishes and do not have surrogates or advance directives, which and whose values should inform decision making for them? We discuss ethical complexities of caring for unrepresented patients.